CASE STUDY World-first clinical trial improves patient outcomes for kidney transplants
Dr Michael Collins
Royal Adelaide Hospital
Filmed August 2023
A world-first clinical trial conducted at the Royal Adelaide Hospital (RAH) and at hospitals across Australia and New Zealand has identified the best fluid treatment to reduce the risk of patients requiring dialysis after a kidney transplant.
Around one in three people who receive a kidney transplant suffer delayed graft function, which means the transplant doesn’t work immediately and they require dialysis.
The lead-author of the study, was Royal Adelaide Hospital Nephrologist and University of Adelaide researcher, Dr Michael Collins.
During the four-year study, fluids were trialled in 808 patients with kidney failure, who received a kidney transplant from a deceased organ donor at the RAH and 15 other hospitals in Australia and New Zealand.
Researchers at the University of Adelaide and University of Sydney, found 30 per cent of participants who received Plasma-Lyte 148 needed dialysis after transplant, compared with 40 per cent of participants who received saline.
The results of the study are now being used to improve the health of kidney transplant patients in Australia and New Zealand and it is likely that practice will change at transplant units around the world.
-
Access to dental care for priority populations
Professor Dileep Sharma is a distinguished dental educator and researcher who currently serves as Professor and Discipline Head of Oral Health at the University of Newcastle, Australia. With over two decades of experience spanning clinical practice, research leadership, and academic mentorship, Professor Sharma has established himself as a leading authority in oral health education and interdisciplinary research.
-
Pathogenicity, modelling & treatment of inherited retinal Stargardt disease
Dr Di Huang is a Research Associate at the Lions Eye Institute (LEI), working with A/Professor Fred Chen and Dr Sam McLenachan. Her research focuses on developing a robust platform of retinal pigment epithelium cells and retinal organoids derived from patient-specific induced pluripotent stem cells to model inherited retinal diseases, particularly Stargardt disease (STGD1).
-
CASE STUDY increasing survival, free of bronchopulmonary dysplasia (BPD) in extremely preterm infants
The aim of the PLUSS trial was to find out if installation of budesonide (a steroid) with surfactant to the lungs of extremely preterm babies helps to prevent lung disease, or Bronchopulmonary dysplasia (BPD).
